Rapport Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 20, null, null, 1.67, 49.66 ], "ebit_estimate": [ -175.93, -232.04, -276.41, -291.4, -298.41 ], "ebitda_estimate": [ -180.1, -256.03, -394.78, -117.58, null ], "net_income_estimate": [ -166.28, -225.46, -271.63, -286.69, -294.16 ], "per_share_eps_estimate": [ -3.46, -4.28, -4.59, -4.8, -4.61 ], "eps_nri_estimate": [ -3.46, -4.36, -4.92, -4.8, -4.61 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 7.23, null, null, null, null ], "pretax_income_estimate": [ -166.01, -225.46, -271.63, -286.69, -294.16 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, 100, 100 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -20.46, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -17.7, "future_eps_nri_estimate_growth": -20.46, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -30.41, "future_ebitda_estimate_growth": -46.58, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -34.66, "future_pretax_income_estimate_growth": -34.69, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, null, null ], "ebit_estimate": [ -48.05, -50.26, -53.47, -57.08, -61.17, -63.58, -65.33 ], "ebitda_estimate": [ -52.22, -51.23, -52.74, -59.75, null, null, null ], "net_income_estimate": [ -45.69, -48.28, -51.77, -54.67, -59.33, -61.94, -63.65 ], "per_share_eps_estimate": [ -0.96, -1, -1.06, -1.15, -1.18, -1.19, -1.21 ], "eps_nri_estimate": [ -0.96, -1, -1.06, -1.16, -1.18, -1.19, -1.21 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 8.85, 8.03, 7.17, null, null, null, null ], "pretax_income_estimate": [ -45.69, -48.28, -51.77, -54.67, -59.33, -61.94, -63.65 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -20.46, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -17.7, "future_eps_nri_estimate_growth": -20.46, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -30.41, "future_ebitda_estimate_growth": -46.58, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -34.66, "future_pretax_income_estimate_growth": -34.69, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }